title: PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
authors.affiliation: Therapeutic Discovery, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, USA. tcushing@amgen.com
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Cushing
authors.forename: Daniela P
authors.initials: DP
authors.lastname: Metz
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Whittington
authors.forename: Lawrence R
authors.initials: LR
authors.lastname: McGee
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000201:enzymology*; D001402:B-Lymphocytes / Q000201:enzymology; D058543:Class Ia Phosphatidylinositol 3-Kinase / Q000737:chemistry / Q000378:metabolism*; D058544:Class Ib Phosphatidylinositol 3-Kinase / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009504:Neutrophils / Q000201:enzymology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011487:Protein Conformation; D013601:T-Lymphocytes / Q000201:enzymology
chemical_list: D007527:Isoenzymes; D000081082:Phosphoinositide-3 Kinase Inhibitors; D058543:Class Ia Phosphatidylinositol 3-Kinase; D058544:Class Ib Phosphatidylinositol 3-Kinase